{"transactions":[{"id":1450564,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":88845,"kind":"organization","name":"venBio Global Strategic Fund III, L.P.","position":1,"cik":"0001739920","reported_name":"venBio Global Strategic Fund III, L.P.","relationship":{"ten_percent_owner":true}},{"id":88846,"kind":"organization","name":"VENBIO GLOBAL STRATEGIC GP III, L.P.","position":2,"cik":"0001869303","reported_name":"VENBIO GLOBAL STRATEGIC GP III, L.P.","relationship":{"ten_percent_owner":true}},{"id":88847,"kind":"organization","name":"VENBIO GLOBAL STRATEGIC GP III, LTD","position":3,"cik":"0001869300","reported_name":"VENBIO GLOBAL STRATEGIC GP III, LTD","relationship":{"ten_percent_owner":true}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":4,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"ten_percent_owner":true}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":5,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"ten_percent_owner":true}}],"security":"Series B Convertible Preferred Stock","published_at":"2024-07-22T20:26:49.000Z","date":"2024-07-22","kind":"exercise","planned":false,"acquired":false,"shares":214692,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a one-for-one basis without payment of further consideration. Upon the closing of the Issuer's initial public offering (the \"IPO\"), the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a one-for-one basis without payment of further consideration. Upon the closing of the Issuer's initial public offering (the \"IPO\"), the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a one-for-one basis without payment of further consideration. Upon the closing of the Issuer's initial public offering (the \"IPO\"), the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a one-for-one basis without payment of further consideration. Upon the closing of the Issuer's initial public offering (the \"IPO\"), the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These securities are held directly by venBio Global Strategic Fund III, L.P., a Cayman Islands partnership (\"venBio III\"). venBio Global Strategic GP III, L.P., a Cayman Islands partnership (\"venBio GP\") is the sole general partner of venBio III. venBio Global Strategic GP III, Ltd., a Cayman Islands company (\"venBio Ltd\") is the sole general partner of venBio GP. Robert Adelman and Corey Goodman, each a citizen of the United States (collectively, the \"Directors\") are each a director of venBio Ltd and may be deemed to share voting and dispositive power over the securities held directly by venBio III. Each of the Directors, together with venBio Ltd and venBio GP, disclaims beneficial ownership over the securities held directly by venBio III except to the extent of their pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":214692},"source":{"system":"sec-edgar","filing":"0000905148-24-001964","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1869303/000090514824001964/form4.xml","form_type":"4"}},{"id":1450563,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":88845,"kind":"organization","name":"venBio Global Strategic Fund III, L.P.","position":1,"cik":"0001739920","reported_name":"venBio Global Strategic Fund III, L.P.","relationship":{"ten_percent_owner":true}},{"id":88846,"kind":"organization","name":"VENBIO GLOBAL STRATEGIC GP III, L.P.","position":2,"cik":"0001869303","reported_name":"VENBIO GLOBAL STRATEGIC GP III, L.P.","relationship":{"ten_percent_owner":true}},{"id":88847,"kind":"organization","name":"VENBIO GLOBAL STRATEGIC GP III, LTD","position":3,"cik":"0001869300","reported_name":"VENBIO GLOBAL STRATEGIC GP III, LTD","relationship":{"ten_percent_owner":true}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":4,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"ten_percent_owner":true}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":5,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"ten_percent_owner":true}}],"security":"Series A Convertible Preferred Stock","published_at":"2024-07-22T20:26:49.000Z","date":"2024-07-22","kind":"exercise","planned":false,"acquired":false,"shares":843592,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a one-for-one basis without payment of further consideration. Upon the closing of the Issuer's initial public offering (the \"IPO\"), the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a one-for-one basis without payment of further consideration. Upon the closing of the Issuer's initial public offering (the \"IPO\"), the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a one-for-one basis without payment of further consideration. Upon the closing of the Issuer's initial public offering (the \"IPO\"), the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a one-for-one basis without payment of further consideration. Upon the closing of the Issuer's initial public offering (the \"IPO\"), the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These securities are held directly by venBio Global Strategic Fund III, L.P., a Cayman Islands partnership (\"venBio III\"). venBio Global Strategic GP III, L.P., a Cayman Islands partnership (\"venBio GP\") is the sole general partner of venBio III. venBio Global Strategic GP III, Ltd., a Cayman Islands company (\"venBio Ltd\") is the sole general partner of venBio GP. Robert Adelman and Corey Goodman, each a citizen of the United States (collectively, the \"Directors\") are each a director of venBio Ltd and may be deemed to share voting and dispositive power over the securities held directly by venBio III. Each of the Directors, together with venBio Ltd and venBio GP, disclaims beneficial ownership over the securities held directly by venBio III except to the extent of their pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":843592},"source":{"system":"sec-edgar","filing":"0000905148-24-001964","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1869303/000090514824001964/form4.xml","form_type":"4"}},{"id":1450562,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":88845,"kind":"organization","name":"venBio Global Strategic Fund III, L.P.","position":1,"cik":"0001739920","reported_name":"venBio Global Strategic Fund III, L.P.","relationship":{"ten_percent_owner":true}},{"id":88846,"kind":"organization","name":"VENBIO GLOBAL STRATEGIC GP III, L.P.","position":2,"cik":"0001869303","reported_name":"VENBIO GLOBAL STRATEGIC GP III, L.P.","relationship":{"ten_percent_owner":true}},{"id":88847,"kind":"organization","name":"VENBIO GLOBAL STRATEGIC GP III, LTD","position":3,"cik":"0001869300","reported_name":"VENBIO GLOBAL STRATEGIC GP III, LTD","relationship":{"ten_percent_owner":true}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":4,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"ten_percent_owner":true}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":5,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2024-07-22T20:26:49.000Z","date":"2024-07-22","kind":"purchase","planned":false,"acquired":true,"shares":416666,"price":12,"value":4999992.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These securities are held directly by venBio Global Strategic Fund III, L.P., a Cayman Islands partnership (\"venBio III\"). venBio Global Strategic GP III, L.P., a Cayman Islands partnership (\"venBio GP\") is the sole general partner of venBio III. venBio Global Strategic GP III, Ltd., a Cayman Islands company (\"venBio Ltd\") is the sole general partner of venBio GP. Robert Adelman and Corey Goodman, each a citizen of the United States (collectively, the \"Directors\") are each a director of venBio Ltd and may be deemed to share voting and dispositive power over the securities held directly by venBio III. Each of the Directors, together with venBio Ltd and venBio GP, disclaims beneficial ownership over the securities held directly by venBio III except to the extent of their pecuniary interest therein."}],"balance_after":1936637,"source":{"system":"sec-edgar","filing":"0000905148-24-001964","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1869303/000090514824001964/form4.xml","form_type":"4"}},{"id":1450561,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":88845,"kind":"organization","name":"venBio Global Strategic Fund III, L.P.","position":1,"cik":"0001739920","reported_name":"venBio Global Strategic Fund III, L.P.","relationship":{"ten_percent_owner":true}},{"id":88846,"kind":"organization","name":"VENBIO GLOBAL STRATEGIC GP III, L.P.","position":2,"cik":"0001869303","reported_name":"VENBIO GLOBAL STRATEGIC GP III, L.P.","relationship":{"ten_percent_owner":true}},{"id":88847,"kind":"organization","name":"VENBIO GLOBAL STRATEGIC GP III, LTD","position":3,"cik":"0001869300","reported_name":"VENBIO GLOBAL STRATEGIC GP III, LTD","relationship":{"ten_percent_owner":true}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":4,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"ten_percent_owner":true}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":5,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2024-07-22T20:26:49.000Z","date":"2024-07-22","kind":"other","planned":false,"acquired":true,"shares":461687,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents the conversion of outstanding simple agreement for future equity in the amount of approximately $4,709,212 into shares of the Issuer's common stock upon closing of the Issuer's IPO at a 15% discount to the $12 IPO price, or $10.20."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the conversion of outstanding simple agreement for future equity in the amount of approximately $4,709,212 into shares of the Issuer's common stock upon closing of the Issuer's IPO at a 15% discount to the $12 IPO price, or $10.20."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These securities are held directly by venBio Global Strategic Fund III, L.P., a Cayman Islands partnership (\"venBio III\"). venBio Global Strategic GP III, L.P., a Cayman Islands partnership (\"venBio GP\") is the sole general partner of venBio III. venBio Global Strategic GP III, Ltd., a Cayman Islands company (\"venBio Ltd\") is the sole general partner of venBio GP. Robert Adelman and Corey Goodman, each a citizen of the United States (collectively, the \"Directors\") are each a director of venBio Ltd and may be deemed to share voting and dispositive power over the securities held directly by venBio III. Each of the Directors, together with venBio Ltd and venBio GP, disclaims beneficial ownership over the securities held directly by venBio III except to the extent of their pecuniary interest therein."}],"balance_after":1519971,"source":{"system":"sec-edgar","filing":"0000905148-24-001964","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1869303/000090514824001964/form4.xml","form_type":"4"}},{"id":1450560,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":88845,"kind":"organization","name":"venBio Global Strategic Fund III, L.P.","position":1,"cik":"0001739920","reported_name":"venBio Global Strategic Fund III, L.P.","relationship":{"ten_percent_owner":true}},{"id":88846,"kind":"organization","name":"VENBIO GLOBAL STRATEGIC GP III, L.P.","position":2,"cik":"0001869303","reported_name":"VENBIO GLOBAL STRATEGIC GP III, L.P.","relationship":{"ten_percent_owner":true}},{"id":88847,"kind":"organization","name":"VENBIO GLOBAL STRATEGIC GP III, LTD","position":3,"cik":"0001869300","reported_name":"VENBIO GLOBAL STRATEGIC GP III, LTD","relationship":{"ten_percent_owner":true}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":4,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"ten_percent_owner":true}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":5,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2024-07-22T20:26:49.000Z","date":"2024-07-22","kind":"exercise","planned":false,"acquired":true,"shares":214692,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a one-for-one basis without payment of further consideration. Upon the closing of the Issuer's initial public offering (the \"IPO\"), the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These securities are held directly by venBio Global Strategic Fund III, L.P., a Cayman Islands partnership (\"venBio III\"). venBio Global Strategic GP III, L.P., a Cayman Islands partnership (\"venBio GP\") is the sole general partner of venBio III. venBio Global Strategic GP III, Ltd., a Cayman Islands company (\"venBio Ltd\") is the sole general partner of venBio GP. Robert Adelman and Corey Goodman, each a citizen of the United States (collectively, the \"Directors\") are each a director of venBio Ltd and may be deemed to share voting and dispositive power over the securities held directly by venBio III. Each of the Directors, together with venBio Ltd and venBio GP, disclaims beneficial ownership over the securities held directly by venBio III except to the extent of their pecuniary interest therein."}],"balance_after":1058284,"source":{"system":"sec-edgar","filing":"0000905148-24-001964","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1869303/000090514824001964/form4.xml","form_type":"4"}},{"id":1450559,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":88845,"kind":"organization","name":"venBio Global Strategic Fund III, L.P.","position":1,"cik":"0001739920","reported_name":"venBio Global Strategic Fund III, L.P.","relationship":{"ten_percent_owner":true}},{"id":88846,"kind":"organization","name":"VENBIO GLOBAL STRATEGIC GP III, L.P.","position":2,"cik":"0001869303","reported_name":"VENBIO GLOBAL STRATEGIC GP III, L.P.","relationship":{"ten_percent_owner":true}},{"id":88847,"kind":"organization","name":"VENBIO GLOBAL STRATEGIC GP III, LTD","position":3,"cik":"0001869300","reported_name":"VENBIO GLOBAL STRATEGIC GP III, LTD","relationship":{"ten_percent_owner":true}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":4,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"ten_percent_owner":true}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":5,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2024-07-22T20:26:49.000Z","date":"2024-07-22","kind":"exercise","planned":false,"acquired":true,"shares":843592,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a one-for-one basis without payment of further consideration. Upon the closing of the Issuer's initial public offering (the \"IPO\"), the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These securities are held directly by venBio Global Strategic Fund III, L.P., a Cayman Islands partnership (\"venBio III\"). venBio Global Strategic GP III, L.P., a Cayman Islands partnership (\"venBio GP\") is the sole general partner of venBio III. venBio Global Strategic GP III, Ltd., a Cayman Islands company (\"venBio Ltd\") is the sole general partner of venBio GP. Robert Adelman and Corey Goodman, each a citizen of the United States (collectively, the \"Directors\") are each a director of venBio Ltd and may be deemed to share voting and dispositive power over the securities held directly by venBio III. Each of the Directors, together with venBio Ltd and venBio GP, disclaims beneficial ownership over the securities held directly by venBio III except to the extent of their pecuniary interest therein."}],"balance_after":843592,"source":{"system":"sec-edgar","filing":"0000905148-24-001964","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1869303/000090514824001964/form4.xml","form_type":"4"}},{"id":1775552,"issuer":{"id":93779,"kind":"organization","name":"RayzeBio, Inc.","symbol":"RYZB"},"owners":[{"id":88845,"kind":"organization","name":"venBio Global Strategic Fund III, L.P.","position":1,"cik":"0001739920","reported_name":"venBio Global Strategic Fund III, L.P.","relationship":{"ten_percent_owner":true}},{"id":88846,"kind":"organization","name":"VENBIO GLOBAL STRATEGIC GP III, L.P.","position":2,"cik":"0001869303","reported_name":"VENBIO GLOBAL STRATEGIC GP III, L.P.","relationship":{"ten_percent_owner":true}},{"id":88847,"kind":"organization","name":"VENBIO GLOBAL STRATEGIC GP III, LTD","position":3,"cik":"0001869300","reported_name":"VENBIO GLOBAL STRATEGIC GP III, LTD","relationship":{"ten_percent_owner":true}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":4,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"ten_percent_owner":true}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":5,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"ten_percent_owner":true}}],"security":"Series C Convertible Preferred Stock","published_at":"2023-09-21T16:30:01.000Z","date":"2023-09-19","kind":"exercise","planned":false,"acquired":false,"shares":216127,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each share of Series C Convertible Preferred Stock (the \"Series C Preferred Stock\") was convertible into shares of Common Stock of the Issuer on a one-for-1.14443753806379 basis. Upon the closing of the Issuer's initial public offering, the Series C Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Series C Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each share of Series C Convertible Preferred Stock (the \"Series C Preferred Stock\") was convertible into shares of Common Stock of the Issuer on a one-for-1.14443753806379 basis. Upon the closing of the Issuer's initial public offering, the Series C Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Series C Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each share of Series C Convertible Preferred Stock (the \"Series C Preferred Stock\") was convertible into shares of Common Stock of the Issuer on a one-for-1.14443753806379 basis. Upon the closing of the Issuer's initial public offering, the Series C Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Series C Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Each share of Series C Convertible Preferred Stock (the \"Series C Preferred Stock\") was convertible into shares of Common Stock of the Issuer on a one-for-1.14443753806379 basis. Upon the closing of the Issuer's initial public offering, the Series C Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Series C Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"These securities are held directly by venBio Global Strategic Fund III, L.P., a Cayman Islands partnership (\"venBio III\"). venBio Global Strategic GP III, L.P., a Cayman Islands partnership (\"venBio GP\") is the sole general partner of venBio III. venBio Global Strategic GP III, Ltd., a Cayman Islands company (\"venBio Ltd\") is the sole general partner of venBio GP. Robert Adelman and Corey Goodman, each a citizen of the United States (collectively, the \"Directors\") are each a director of venBio Ltd and may be deemed to share voting and dispositive power over the securities held directly by venBio III. Each of the Directors, together with venBio Ltd and venBio GP, disclaims beneficial ownership over the securities held directly by venBio III except to the extent of their pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":247343},"source":{"system":"sec-edgar","filing":"0000905148-23-000957","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1869303/000090514823000957/form4.xml","form_type":"4"}},{"id":1775551,"issuer":{"id":93779,"kind":"organization","name":"RayzeBio, Inc.","symbol":"RYZB"},"owners":[{"id":88845,"kind":"organization","name":"venBio Global Strategic Fund III, L.P.","position":1,"cik":"0001739920","reported_name":"venBio Global Strategic Fund III, L.P.","relationship":{"ten_percent_owner":true}},{"id":88846,"kind":"organization","name":"VENBIO GLOBAL STRATEGIC GP III, L.P.","position":2,"cik":"0001869303","reported_name":"VENBIO GLOBAL STRATEGIC GP III, L.P.","relationship":{"ten_percent_owner":true}},{"id":88847,"kind":"organization","name":"VENBIO GLOBAL STRATEGIC GP III, LTD","position":3,"cik":"0001869300","reported_name":"VENBIO GLOBAL STRATEGIC GP III, LTD","relationship":{"ten_percent_owner":true}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":4,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"ten_percent_owner":true}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":5,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"ten_percent_owner":true}}],"security":"Series B Convertible Preferred Stock","published_at":"2023-09-21T16:30:01.000Z","date":"2023-09-19","kind":"exercise","planned":false,"acquired":false,"shares":1123862,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each share of Series B Convertible Preferred Stock (the \"Series B Preferred Stock\") was convertible into shares of Common Stock of the Issuer on a one-for-one basis. Upon the closing of the Issuer's initial public offering, the Series B Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Series B Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of Series B Convertible Preferred Stock (the \"Series B Preferred Stock\") was convertible into shares of Common Stock of the Issuer on a one-for-one basis. Upon the closing of the Issuer's initial public offering, the Series B Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Series B Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each share of Series B Convertible Preferred Stock (the \"Series B Preferred Stock\") was convertible into shares of Common Stock of the Issuer on a one-for-one basis. Upon the closing of the Issuer's initial public offering, the Series B Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Series B Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each share of Series B Convertible Preferred Stock (the \"Series B Preferred Stock\") was convertible into shares of Common Stock of the Issuer on a one-for-one basis. Upon the closing of the Issuer's initial public offering, the Series B Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Series B Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"These securities are held directly by venBio Global Strategic Fund III, L.P., a Cayman Islands partnership (\"venBio III\"). venBio Global Strategic GP III, L.P., a Cayman Islands partnership (\"venBio GP\") is the sole general partner of venBio III. venBio Global Strategic GP III, Ltd., a Cayman Islands company (\"venBio Ltd\") is the sole general partner of venBio GP. Robert Adelman and Corey Goodman, each a citizen of the United States (collectively, the \"Directors\") are each a director of venBio Ltd and may be deemed to share voting and dispositive power over the securities held directly by venBio III. Each of the Directors, together with venBio Ltd and venBio GP, disclaims beneficial ownership over the securities held directly by venBio III except to the extent of their pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1123862},"source":{"system":"sec-edgar","filing":"0000905148-23-000957","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1869303/000090514823000957/form4.xml","form_type":"4"}},{"id":1775550,"issuer":{"id":93779,"kind":"organization","name":"RayzeBio, Inc.","symbol":"RYZB"},"owners":[{"id":88845,"kind":"organization","name":"venBio Global Strategic Fund III, L.P.","position":1,"cik":"0001739920","reported_name":"venBio Global Strategic Fund III, L.P.","relationship":{"ten_percent_owner":true}},{"id":88846,"kind":"organization","name":"VENBIO GLOBAL STRATEGIC GP III, L.P.","position":2,"cik":"0001869303","reported_name":"VENBIO GLOBAL STRATEGIC GP III, L.P.","relationship":{"ten_percent_owner":true}},{"id":88847,"kind":"organization","name":"VENBIO GLOBAL STRATEGIC GP III, LTD","position":3,"cik":"0001869300","reported_name":"VENBIO GLOBAL STRATEGIC GP III, LTD","relationship":{"ten_percent_owner":true}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":4,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"ten_percent_owner":true}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":5,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"ten_percent_owner":true}}],"security":"Series A Convertible Preferred Stock","published_at":"2023-09-21T16:30:01.000Z","date":"2023-09-19","kind":"exercise","planned":false,"acquired":false,"shares":3786957,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Convertible Preferred Stock (the \"Series A Preferred Stock\") was convertible into shares of Common Stock of the Issuer on a one-for-one basis. Upon the closing of the Issuer's initial public offering, the Series A Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Series A Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Convertible Preferred Stock (the \"Series A Preferred Stock\") was convertible into shares of Common Stock of the Issuer on a one-for-one basis. Upon the closing of the Issuer's initial public offering, the Series A Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Series A Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Convertible Preferred Stock (the \"Series A Preferred Stock\") was convertible into shares of Common Stock of the Issuer on a one-for-one basis. Upon the closing of the Issuer's initial public offering, the Series A Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Series A Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Convertible Preferred Stock (the \"Series A Preferred Stock\") was convertible into shares of Common Stock of the Issuer on a one-for-one basis. Upon the closing of the Issuer's initial public offering, the Series A Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Series A Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"These securities are held directly by venBio Global Strategic Fund III, L.P., a Cayman Islands partnership (\"venBio III\"). venBio Global Strategic GP III, L.P., a Cayman Islands partnership (\"venBio GP\") is the sole general partner of venBio III. venBio Global Strategic GP III, Ltd., a Cayman Islands company (\"venBio Ltd\") is the sole general partner of venBio GP. Robert Adelman and Corey Goodman, each a citizen of the United States (collectively, the \"Directors\") are each a director of venBio Ltd and may be deemed to share voting and dispositive power over the securities held directly by venBio III. Each of the Directors, together with venBio Ltd and venBio GP, disclaims beneficial ownership over the securities held directly by venBio III except to the extent of their pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3786957},"source":{"system":"sec-edgar","filing":"0000905148-23-000957","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1869303/000090514823000957/form4.xml","form_type":"4"}},{"id":1775549,"issuer":{"id":93779,"kind":"organization","name":"RayzeBio, Inc.","symbol":"RYZB"},"owners":[{"id":88845,"kind":"organization","name":"venBio Global Strategic Fund III, L.P.","position":1,"cik":"0001739920","reported_name":"venBio Global Strategic Fund III, L.P.","relationship":{"ten_percent_owner":true}},{"id":88846,"kind":"organization","name":"VENBIO GLOBAL STRATEGIC GP III, L.P.","position":2,"cik":"0001869303","reported_name":"VENBIO GLOBAL STRATEGIC GP III, L.P.","relationship":{"ten_percent_owner":true}},{"id":88847,"kind":"organization","name":"VENBIO GLOBAL STRATEGIC GP III, LTD","position":3,"cik":"0001869300","reported_name":"VENBIO GLOBAL STRATEGIC GP III, LTD","relationship":{"ten_percent_owner":true}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":4,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"ten_percent_owner":true}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":5,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2023-09-21T16:30:01.000Z","date":"2023-09-19","kind":"exercise","planned":false,"acquired":true,"shares":247343,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each share of Series C Convertible Preferred Stock (the \"Series C Preferred Stock\") was convertible into shares of Common Stock of the Issuer on a one-for-1.14443753806379 basis. Upon the closing of the Issuer's initial public offering, the Series C Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Series C Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"These securities are held directly by venBio Global Strategic Fund III, L.P., a Cayman Islands partnership (\"venBio III\"). venBio Global Strategic GP III, L.P., a Cayman Islands partnership (\"venBio GP\") is the sole general partner of venBio III. venBio Global Strategic GP III, Ltd., a Cayman Islands company (\"venBio Ltd\") is the sole general partner of venBio GP. Robert Adelman and Corey Goodman, each a citizen of the United States (collectively, the \"Directors\") are each a director of venBio Ltd and may be deemed to share voting and dispositive power over the securities held directly by venBio III. Each of the Directors, together with venBio Ltd and venBio GP, disclaims beneficial ownership over the securities held directly by venBio III except to the extent of their pecuniary interest therein."}],"balance_after":5158162,"source":{"system":"sec-edgar","filing":"0000905148-23-000957","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1869303/000090514823000957/form4.xml","form_type":"4"}},{"id":1775548,"issuer":{"id":93779,"kind":"organization","name":"RayzeBio, Inc.","symbol":"RYZB"},"owners":[{"id":88845,"kind":"organization","name":"venBio Global Strategic Fund III, L.P.","position":1,"cik":"0001739920","reported_name":"venBio Global Strategic Fund III, L.P.","relationship":{"ten_percent_owner":true}},{"id":88846,"kind":"organization","name":"VENBIO GLOBAL STRATEGIC GP III, L.P.","position":2,"cik":"0001869303","reported_name":"VENBIO GLOBAL STRATEGIC GP III, L.P.","relationship":{"ten_percent_owner":true}},{"id":88847,"kind":"organization","name":"VENBIO GLOBAL STRATEGIC GP III, LTD","position":3,"cik":"0001869300","reported_name":"VENBIO GLOBAL STRATEGIC GP III, LTD","relationship":{"ten_percent_owner":true}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":4,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"ten_percent_owner":true}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":5,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2023-09-21T16:30:01.000Z","date":"2023-09-19","kind":"exercise","planned":false,"acquired":true,"shares":1123862,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of Series B Convertible Preferred Stock (the \"Series B Preferred Stock\") was convertible into shares of Common Stock of the Issuer on a one-for-one basis. Upon the closing of the Issuer's initial public offering, the Series B Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Series B Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"These securities are held directly by venBio Global Strategic Fund III, L.P., a Cayman Islands partnership (\"venBio III\"). venBio Global Strategic GP III, L.P., a Cayman Islands partnership (\"venBio GP\") is the sole general partner of venBio III. venBio Global Strategic GP III, Ltd., a Cayman Islands company (\"venBio Ltd\") is the sole general partner of venBio GP. Robert Adelman and Corey Goodman, each a citizen of the United States (collectively, the \"Directors\") are each a director of venBio Ltd and may be deemed to share voting and dispositive power over the securities held directly by venBio III. Each of the Directors, together with venBio Ltd and venBio GP, disclaims beneficial ownership over the securities held directly by venBio III except to the extent of their pecuniary interest therein."}],"balance_after":4910819,"source":{"system":"sec-edgar","filing":"0000905148-23-000957","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1869303/000090514823000957/form4.xml","form_type":"4"}},{"id":1775547,"issuer":{"id":93779,"kind":"organization","name":"RayzeBio, Inc.","symbol":"RYZB"},"owners":[{"id":88845,"kind":"organization","name":"venBio Global Strategic Fund III, L.P.","position":1,"cik":"0001739920","reported_name":"venBio Global Strategic Fund III, L.P.","relationship":{"ten_percent_owner":true}},{"id":88846,"kind":"organization","name":"VENBIO GLOBAL STRATEGIC GP III, L.P.","position":2,"cik":"0001869303","reported_name":"VENBIO GLOBAL STRATEGIC GP III, L.P.","relationship":{"ten_percent_owner":true}},{"id":88847,"kind":"organization","name":"VENBIO GLOBAL STRATEGIC GP III, LTD","position":3,"cik":"0001869300","reported_name":"VENBIO GLOBAL STRATEGIC GP III, LTD","relationship":{"ten_percent_owner":true}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":4,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"ten_percent_owner":true}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":5,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2023-09-21T16:30:01.000Z","date":"2023-09-19","kind":"exercise","planned":false,"acquired":true,"shares":3786957,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Convertible Preferred Stock (the \"Series A Preferred Stock\") was convertible into shares of Common Stock of the Issuer on a one-for-one basis. Upon the closing of the Issuer's initial public offering, the Series A Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Series A Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"These securities are held directly by venBio Global Strategic Fund III, L.P., a Cayman Islands partnership (\"venBio III\"). venBio Global Strategic GP III, L.P., a Cayman Islands partnership (\"venBio GP\") is the sole general partner of venBio III. venBio Global Strategic GP III, Ltd., a Cayman Islands company (\"venBio Ltd\") is the sole general partner of venBio GP. Robert Adelman and Corey Goodman, each a citizen of the United States (collectively, the \"Directors\") are each a director of venBio Ltd and may be deemed to share voting and dispositive power over the securities held directly by venBio III. Each of the Directors, together with venBio Ltd and venBio GP, disclaims beneficial ownership over the securities held directly by venBio III except to the extent of their pecuniary interest therein."}],"balance_after":3786957,"source":{"system":"sec-edgar","filing":"0000905148-23-000957","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1869303/000090514823000957/form4.xml","form_type":"4"}},{"id":2236391,"issuer":{"id":62843,"kind":"organization","name":"Ventyx Biosciences, Inc.","symbol":"VTYX"},"owners":[{"id":88845,"kind":"organization","name":"venBio Global Strategic Fund III, L.P.","position":1,"cik":"0001739920","reported_name":"venBio Global Strategic Fund III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":88846,"kind":"organization","name":"VENBIO GLOBAL STRATEGIC GP III, L.P.","position":2,"cik":"0001869303","reported_name":"VENBIO GLOBAL STRATEGIC GP III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":88847,"kind":"organization","name":"VENBIO GLOBAL STRATEGIC GP III, LTD","position":3,"cik":"0001869300","reported_name":"VENBIO GLOBAL STRATEGIC GP III, LTD","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":4,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":5,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-10T18:22:36.000Z","date":"2022-06-09","kind":"grant","acquired":true,"shares":13301,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest on the earlier of (i) the one-year anniversary of the date of grant or, (ii) the day prior to the date of the Annual Meeting of the Issuer's stockholders next following the date the option was granted, in each case, subject to the relevant director (Dr. Royston and Dr. Gaster) continuing to be Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through the applicable vesting date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents options awarded to Richard Gaster, a partner of venBio Global Strategic GP III, L.P. (\"venBio GP\"), pursuant to the annual equity grant under the Issuer's non-employee director compensation policy.  These options are held for the benefit of venBio III. Pursuant to policies of venBio Partners, the manager of venBio III, with respect to director compensation, upon the exercise of these options and sale of the underlying securities, the proceeds will be remitted to venBio III. Dr. Gaster disclaims beneficial ownership over the shares underlying the options held for the benefit of venBio III."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"venBio GP is the sole general partner of venBio III. venBio Ltd. is the sole general partner of venBio GP. Dr. Royston, Robert Adelman and Corey Goodman (collectively, the \"Directors\") are each a director of venBio Ltd and may be deemed to share voting and dispositive power over the shares held by venBio III. Each of the Directors, together with venBio Ltd and venBio GP, disclaims beneficial ownership over the shares underlying the options held for the benefit of venBio III except to the extent of their pecuniary interest therein."}],"balance_after":13301,"derivative":{"exercise_price":16.54,"expiration_date":"2032-06-09","underlying":"Common Stock","underlying_shares":13301},"source":{"system":"sec-edgar","filing":"0001567619-22-012695","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1869303/000156761922012695/doc1.xml","form_type":"4"}},{"id":2236390,"issuer":{"id":62843,"kind":"organization","name":"Ventyx Biosciences, Inc.","symbol":"VTYX"},"owners":[{"id":88845,"kind":"organization","name":"venBio Global Strategic Fund III, L.P.","position":1,"cik":"0001739920","reported_name":"venBio Global Strategic Fund III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":88846,"kind":"organization","name":"VENBIO GLOBAL STRATEGIC GP III, L.P.","position":2,"cik":"0001869303","reported_name":"VENBIO GLOBAL STRATEGIC GP III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":88847,"kind":"organization","name":"VENBIO GLOBAL STRATEGIC GP III, LTD","position":3,"cik":"0001869300","reported_name":"VENBIO GLOBAL STRATEGIC GP III, LTD","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":4,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":5,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-10T18:22:36.000Z","date":"2022-06-09","kind":"grant","acquired":true,"shares":13301,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest on the earlier of (i) the one-year anniversary of the date of grant or, (ii) the day prior to the date of the Annual Meeting of the Issuer's stockholders next following the date the option was granted, in each case, subject to the relevant director (Dr. Royston and Dr. Gaster) continuing to be Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through the applicable vesting date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents options awarded to Aaron Royston, a director and partner of venBio Global Strategic GP III, Ltd. (\"venBio Ltd\"), pursuant to the annual equity grant under the Issuer's non-employee director compensation policy.  These options are held for the benefit of venBio Global Strategic Fund III, L.P. (\"venBio III\"). Pursuant to policies of venBio Partners, the manager of venBio III, with respect to director compensation, upon the exercise of these options and sale of the underlying securities, the proceeds will be remitted to venBio III. Dr. Royston disclaims beneficial ownership over the shares underlying the options held for the benefit of venBio III except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"venBio GP is the sole general partner of venBio III. venBio Ltd. is the sole general partner of venBio GP. Dr. Royston, Robert Adelman and Corey Goodman (collectively, the \"Directors\") are each a director of venBio Ltd and may be deemed to share voting and dispositive power over the shares held by venBio III. Each of the Directors, together with venBio Ltd and venBio GP, disclaims beneficial ownership over the shares underlying the options held for the benefit of venBio III except to the extent of their pecuniary interest therein."}],"balance_after":13301,"derivative":{"exercise_price":16.54,"expiration_date":"2032-06-09","underlying":"Common Stock","underlying_shares":13301},"source":{"system":"sec-edgar","filing":"0001567619-22-012695","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1869303/000156761922012695/doc1.xml","form_type":"4"}},{"id":2535681,"issuer":{"id":62843,"kind":"organization","name":"Ventyx Biosciences, Inc.","symbol":"VTYX"},"owners":[{"id":88845,"kind":"organization","name":"venBio Global Strategic Fund III, L.P.","position":1,"cik":"0001739920","reported_name":"venBio Global Strategic Fund III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":88846,"kind":"organization","name":"VENBIO GLOBAL STRATEGIC GP III, L.P.","position":2,"cik":"0001869303","reported_name":"VENBIO GLOBAL STRATEGIC GP III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":88847,"kind":"organization","name":"VENBIO GLOBAL STRATEGIC GP III, LTD","position":3,"cik":"0001869300","reported_name":"VENBIO GLOBAL STRATEGIC GP III, LTD","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":4,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":5,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}}],"security":"Series B Preferred Stock","published_at":"2021-10-25T19:40:28.000Z","date":"2021-10-25","kind":"exercise","acquired":false,"shares":395027,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"All shares of the preferred stock, par value $0.0001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.0001 per share (\"Common Stock\") immediately prior to the closing of the Issuer's initial public offering of its Common Stock.  The preferred stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All shares of the preferred stock, par value $0.0001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.0001 per share (\"Common Stock\") immediately prior to the closing of the Issuer's initial public offering of its Common Stock.  The preferred stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"All shares of the preferred stock, par value $0.0001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.0001 per share (\"Common Stock\") immediately prior to the closing of the Issuer's initial public offering of its Common Stock.  The preferred stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Shares held by venBio III. venBio GP is the sole general partner of venBio III.  venBio Ltd is the sole general partner of venBio GP.  The Directors are each a director of venBio Ltd and may be deemed to share voting and dispositive power over the shares held by venBio III. Each of the Directors, together with venBio Ltd and venBio GP, disclaims beneficial ownership over the shares held by venBio III except to the extent of their pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":395027},"source":{"system":"sec-edgar","filing":"0001567619-21-018677","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1869303/000156761921018677/doc1.xml","form_type":"4"}},{"id":2535680,"issuer":{"id":62843,"kind":"organization","name":"Ventyx Biosciences, Inc.","symbol":"VTYX"},"owners":[{"id":88845,"kind":"organization","name":"venBio Global Strategic Fund III, L.P.","position":1,"cik":"0001739920","reported_name":"venBio Global Strategic Fund III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":88846,"kind":"organization","name":"VENBIO GLOBAL STRATEGIC GP III, L.P.","position":2,"cik":"0001869303","reported_name":"VENBIO GLOBAL STRATEGIC GP III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":88847,"kind":"organization","name":"VENBIO GLOBAL STRATEGIC GP III, LTD","position":3,"cik":"0001869300","reported_name":"VENBIO GLOBAL STRATEGIC GP III, LTD","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":4,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":5,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}}],"security":"Series A Preferred Stock","published_at":"2021-10-25T19:40:28.000Z","date":"2021-10-25","kind":"exercise","acquired":false,"shares":3289742,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"All shares of the preferred stock, par value $0.0001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.0001 per share (\"Common Stock\") immediately prior to the closing of the Issuer's initial public offering of its Common Stock.  The preferred stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All shares of the preferred stock, par value $0.0001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.0001 per share (\"Common Stock\") immediately prior to the closing of the Issuer's initial public offering of its Common Stock.  The preferred stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"All shares of the preferred stock, par value $0.0001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.0001 per share (\"Common Stock\") immediately prior to the closing of the Issuer's initial public offering of its Common Stock.  The preferred stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Shares held by venBio III. venBio GP is the sole general partner of venBio III.  venBio Ltd is the sole general partner of venBio GP.  The Directors are each a director of venBio Ltd and may be deemed to share voting and dispositive power over the shares held by venBio III. Each of the Directors, together with venBio Ltd and venBio GP, disclaims beneficial ownership over the shares held by venBio III except to the extent of their pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3289742},"source":{"system":"sec-edgar","filing":"0001567619-21-018677","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1869303/000156761921018677/doc1.xml","form_type":"4"}},{"id":2535679,"issuer":{"id":62843,"kind":"organization","name":"Ventyx Biosciences, Inc.","symbol":"VTYX"},"owners":[{"id":88845,"kind":"organization","name":"venBio Global Strategic Fund III, L.P.","position":1,"cik":"0001739920","reported_name":"venBio Global Strategic Fund III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":88846,"kind":"organization","name":"VENBIO GLOBAL STRATEGIC GP III, L.P.","position":2,"cik":"0001869303","reported_name":"VENBIO GLOBAL STRATEGIC GP III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":88847,"kind":"organization","name":"VENBIO GLOBAL STRATEGIC GP III, LTD","position":3,"cik":"0001869300","reported_name":"VENBIO GLOBAL STRATEGIC GP III, LTD","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":4,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":5,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}}],"security":"Common Stock","published_at":"2021-10-25T19:40:28.000Z","date":"2021-10-25","kind":"purchase","acquired":true,"shares":312500,"price":16,"value":5000000.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Shares held by venBio III. venBio GP is the sole general partner of venBio III.  venBio Ltd is the sole general partner of venBio GP.  The Directors are each a director of venBio Ltd and may be deemed to share voting and dispositive power over the shares held by venBio III. Each of the Directors, together with venBio Ltd and venBio GP, disclaims beneficial ownership over the shares held by venBio III except to the extent of their pecuniary interest therein."}],"balance_after":3997269,"source":{"system":"sec-edgar","filing":"0001567619-21-018677","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1869303/000156761921018677/doc1.xml","form_type":"4"}},{"id":2535678,"issuer":{"id":62843,"kind":"organization","name":"Ventyx Biosciences, Inc.","symbol":"VTYX"},"owners":[{"id":88845,"kind":"organization","name":"venBio Global Strategic Fund III, L.P.","position":1,"cik":"0001739920","reported_name":"venBio Global Strategic Fund III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":88846,"kind":"organization","name":"VENBIO GLOBAL STRATEGIC GP III, L.P.","position":2,"cik":"0001869303","reported_name":"VENBIO GLOBAL STRATEGIC GP III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":88847,"kind":"organization","name":"VENBIO GLOBAL STRATEGIC GP III, LTD","position":3,"cik":"0001869300","reported_name":"VENBIO GLOBAL STRATEGIC GP III, LTD","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":88848,"kind":"person","name":"Adelman Robert J","position":4,"cik":"0001329161","reported_name":"Adelman Robert J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":17062,"kind":"person","name":"GOODMAN COREY S","position":5,"cik":"0001278411","reported_name":"GOODMAN COREY S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}}],"security":"Common Stock","published_at":"2021-10-25T19:40:28.000Z","date":"2021-10-25","kind":"exercise","acquired":true,"shares":3684769,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of the preferred stock, par value $0.0001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.0001 per share (\"Common Stock\") immediately prior to the closing of the Issuer's initial public offering of its Common Stock.  The preferred stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Shares held by venBio III. venBio GP is the sole general partner of venBio III.  venBio Ltd is the sole general partner of venBio GP.  The Directors are each a director of venBio Ltd and may be deemed to share voting and dispositive power over the shares held by venBio III. Each of the Directors, together with venBio Ltd and venBio GP, disclaims beneficial ownership over the shares held by venBio III except to the extent of their pecuniary interest therein."}],"balance_after":3684769,"source":{"system":"sec-edgar","filing":"0001567619-21-018677","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1869303/000156761921018677/doc1.xml","form_type":"4"}}]}